Welcome Dr. Kemal Malik to our Board of Directors! An accomplished industry executive with 30 years of experience in global pharmaceutical research, Dr. Malik’s deep expertise will be invaluable as we expand the reach of cell therapy to #autoimmunity. Read here: https://bit.ly/45RblsM
Cartesian Therapeutics
Biotechnology Research
Gaithersburg, MD 3,645 followers
Pioneering RNA cell therapy for autoimmune disease
About us
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit https://www.cartesiantherapeutics.com/ or follow us on LinkedIn @Cartesian-Therapeutics.
- Website
-
http://www.cartesiantherapeutics.com
External link for Cartesian Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Gaithersburg, MD
- Type
- Public Company
- Founded
- 2016
- Specialties
- Immunotherapy, Oncology, Molecular Biology, Immunology, Autoimmune Diseases, Myasthenia Gravis, ARDS, Cell Therapy, Lung disease, NETs, Cardiovascular Disease, Gene Therapy, Cancer Research, and multiple myeloma
Locations
-
Primary
Get directions
Gaithersburg, MD 20878, US
Employees at Cartesian Therapeutics
-
Christopher M. Jewell
Chief Scientific Officer, Cartesian Therapeutics | MPower Professor and Institute Professor of Translational Engineering | Biotechnology Consultant
-
Heng Xu
Research Scientist at Cartesian Therapeutics
-
Jessica Keliher, SPHR
Human Resources Leader & Executive Leadership Coach
-
Carsten Brunn
President and CEO
Updates
-
We recently announced dosing of the first patient in our Phase 2 trial of Descartes-08 in patients with #SLE. Cartesian’s approach is designed to overcome the limitations of conventional DNA-engineered CAR-T cell therapies for #autoimmunediseases. Read more: https://bit.ly/3Wbmku4
-
-
Today marks an important milestone for Cartesian as we share positive topline results from our Phase 2b trial of Descartes-08 in patients with #myastheniagravis. Descartes-08 is the first mRNA cell therapy designed to treat MG. Learn more about the results and next steps as we continue our journey to treat #autoimmunediseases: https://bit.ly/3xJjvXA
-
#MyastheniaGravis remains underdiagnosed and often mistaken for other diseases. During #MyastheniaGravisAwarenessMonth, we’re highlighting symptoms to be aware of for yourself and loved ones. With no current cure for MG, we’re proud to be developing our lead program Descartes-08, currently in a Phase 2b trial: https://bit.ly/49X50wb
-
-
Cartesian’s CEO Carsten Brunn recently joined the #BioBlast podcast with Devin Zitelman and discussed topics from culture to pipeline development, and excitement around our new headquarters and manufacturing facility in Frederick, MD, which will support the development of our innovative cell therapies aiming to treat #autoimmunediseases. Full interview here: https://bit.ly/4eoR2Xs
After productive time off including a trip to the Biotechnology Innovation Organization Conference in San Diego we're back with the next episode of #BioBlast!👏 👏 👏 Devin Zitelman connects with Carsten Brunn, President & CEO, Cartesian Therapeutics (NASDAQ: RNAC), a publicly traded, clinical-stage #biotech company pioneering #mRNA cell therapy for autoimmune diseases. The two discuss the company's $110M reverse-merger with Selecta Biosciences, plus: 🔎 Professional story and career "arcs" that inform his leadership style and management approach. ☕ The integration of founder (Murat Kalayoglu + Michael Singer) and executive teams, approach to culture-building and talent acquisition. 💉 Managing a pipeline of novel assets across multiple indications and phases of clinical trials. 🔭 Differences and advantages of hosting operations in #Boston and #Maryland including their biomanufacturing + GMP facilities. 💰 Trends in venture and development capital. ...and more! 📹 Tune in and subscribe to #BioBlast, now streaming on YouTube & Spotify for Podcasters plus anywhere you access your #podcasts. MassBio Maryland Tech Council Maryland Department of Commerce BioBuzz Nasdaq Frederick Innovative Technology Center, Inc Argot Partners Scheer Partners Velogic The National Institutes of Health Disclaimer: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners employs individuals that own shares in Cartesian Therapeutics stock.
Ep 17 - A Conversation with Carsten Brunn of Cartesian Therapeutics
https://www.youtube.com/
-
It’s #MyastheniaGravisAwarenessMonth. Committed to developing potent yet safer cell therapies for patients with #autoimmunediseases, we’re evaluating Descartes-08, our lead product candidate for the treatment of MG, in a Phase 2b trial. Learn more: https://bit.ly/49X50wb
-
-
Cartesian’s COO Metin Kurtoglu recently attended the 2024 National Lupus Advocacy Summit held by the Lupus Foundation of America, Inc. The event highlighted the continued need for #lupus research and funding and we’re proud to support this important cause.
-
-
We’re honored to be chosen as Breakthrough Company of the Year at last night’s annual BioBuzz awards, which celebrates innovative and impactful biotech companies in our region. This award is a reflection of our talented team at Cartesian. Thank you for the recognition!
-
-
Our CMO, Milos Miljkovic, MD, recently presented on mRNA cell therapy at the LuCIN Community Meeting. Cartesian is proud to have participated in this event, which was hosted by Lupus Therapeutics, an affiliate of Lupus Research Alliance, an organization funding research for #lupus.
-
-
Today, we announced the Regenerative Medicine Advanced Therapy designation from the #FDA for Descartes-08, our lead mRNA #celltherapy product candidate, underscoring our belief of its potential as a treatment for #myastheniagravis. Learn more: https://bit.ly/3WSzSLA
-